ClinicalTrials.gg

Program

QHRD106

A development code. Also written as “QHRD106 Injection”, “QHRD106 Injection (Low-dose group)” and “QHRD106 Injection (Middle-dose group)”.

Its studies are mostly in Ischemic Stroke, led by Changzhou Qianhong Bio-pharma.

Furthest: phase 2, since Feb 1, 20263 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changzhou Qianhong Bio-pharma31 open or runningphase 2since Feb 1, 2026Apr 16, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2024First studies: 2 phase 1 studies in Ischemic StrokeFirst studyNCT06380699, NCT06388772
  2. Feb 1, 2026Phase 2 study in Ischemic StrokePhase 2 reachedNCT07396337 · 320 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07396337Ischemic Stroke · China2RecruitingOct 31, 2026320
NCT06388772Ischemic Stroke · China1CompletedJul 22, 202274
NCT06380699Ischemic Stroke · China1CompletedNov 16, 202356

How it is read

Names in the registry

  • “QHRD106 Injection”, 2 entries
  • “QHRD106 Injection (Low-dose group)”, 1 entry
  • “QHRD106 Injection (Middle-dose group)”, 1 entry
  • “QHRD106 Injection (High-dose group)”, 1 entry

Codes read as this program: QHRD106.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.